Literature DB >> 27986567

Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition.

Lei Shao1, Huanjie Li2, Jian Chen2, Haibo Song3, Yuzhu Zhang3, Fei Wu3, Wenjuan Wang3, Wen Zhang3, Fang Wang3, Hui Li3, Dongqi Tang4.   

Abstract

Irisin is involved in promoting metabolism, immune regulation, and affects chronic inflammation in many systemic diseases, including gastric cancer. However, the role of irisin in lung cancer is not well characterized. To determine whether irisin has a protective effect against lung cancer, we cultured A549 and NCI-H446 lung cancer cells and treated them with irisin. We detected the proliferation by MTT assay, and assessed the migration and invasion of the cells by scratch wound healing assay and Tran-swell assay. The expression levels of epithelial-to-mesenchymal transition (EMT) markers and the related signaling pathways were detected by western blot analysis. Meanwhile, an inhibitor of PI3K was used to investigate the effect of irsin. Finally, the expression of Snail was detected. We demonstrated that irisin inhibits the proliferation, migration, and invasion of lung cancer cells, and has a novel role in mediating the PI3K/AKT pathway in the cells. Irisin can reverse the activity of EMT and inhibit the expression of Snail via mediating the PI3K/AKT pathway, which is a key regulator of Snail. These results revealed that irisin inhibited EMT and reduced the invasion of lung cancer cells via the PI3K/AKT/Snail pathway.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  EMT; Irisin; Lung cancer; PI3K/AKT/Snail pathway

Mesh:

Substances:

Year:  2016        PMID: 27986567     DOI: 10.1016/j.bbrc.2016.12.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Authors:  Shun Sasaki; Eiji Oki; Hiroshi Saeki; Takayuki Shimose; Sanae Sakamoto; Qingjiang Hu; Kensuke Kudo; Yasuo Tsuda; Yuichiro Nakashima; Koji Ando; Yoshito Akagi; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2019-05-06       Impact factor: 3.402

2.  The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines.

Authors:  Atiye Saeedi Sadr; Hassan Ehteram; Elahe Seyed Hosseini; Marziyeh Alizadeh Zarei; Hassan Hassani Bafrani; Hamed Haddad Kashani
Journal:  Oncol Ther       Date:  2022-04-25

3.  Irisin and Carcinoembryonic Antigen (CEA) as Potential Diagnostic Biomarkers in Gastric and Colorectal Cancers.

Authors:  Ahmed Abd Temur; Farah Aqeel Rashid
Journal:  Rep Biochem Mol Biol       Date:  2021-10

4.  Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway.

Authors:  Ting Zhu; Weina Zhang; Yumin Zhang; Enbang Lu; Huayuan Liu; Xinyue Liu; Suwei Yin; Ping Zhang
Journal:  Arch Gynecol Obstet       Date:  2022-02-14       Impact factor: 2.493

5.  Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway.

Authors:  Gang Kong; Yunpeng Jiang; Xiujiang Sun; Zhilin Cao; Guodong Zhang; Zhongyuan Zhao; Yong Zhao; Qian Yu; Gong Cheng
Journal:  Oncol Rep       Date:  2017-09-20       Impact factor: 3.906

6.  Cutaneous transcriptome analysis in NIH hairless mice.

Authors:  Zhong-Hao Ji; Jian Chen; Wei Gao; Jin-Yu Zhang; Fu-Shi Quan; Jin-Ping Hu; Bao Yuan; Wen-Zhi Ren
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

7.  Serum irisin associates with breast cancer to spinal metastasis.

Authors:  Zheng-Ping Zhang; Xue-Fang Zhang; Hui Li; Tuan-Jiang Liu; Qin-Peng Zhao; Lin-Hong Huang; Zi-Jun Cao; Li-Min He; Ding-Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.817

Review 8.  Exercise-induced myokines and their effect on prostate cancer.

Authors:  Jin-Soo Kim; Daniel A Galvão; Robert U Newton; Elin Gray; Dennis R Taaffe
Journal:  Nat Rev Urol       Date:  2021-06-22       Impact factor: 14.432

Review 9.  Current Evidence of the Role of the Myokine Irisin in Cancer.

Authors:  Evangelia Tsiani; Nicole Tsakiridis; Rozalia Kouvelioti; Alina Jaglanian; Panagiota Klentrou
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 10.  The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease.

Authors:  Wen-Lu Ou-Yang; Bei Guo; Feng Xu; Xiao Lin; Fu-Xing-Zi Li; Su-Kang Shan; Feng Wu; Yi Wang; Ming-Hui Zheng; Qiu-Shuang Xu; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.